°æºÏÁö¿ª ¼³»çȯÀÚ¿¡¼­ ºÐ¸®µÈ Salmonella ±ÕÀÇ Æ¯¼º ºÐ¼®
Characterization of Salmonella spp. Clinical Isolates in Gyeongsangbuk-do Province, 2012 to 2013Background: Extended-spectrum cephalosporins and fluoroquinolones are important antimicrobials for treating invasive salmonellosis, and emerging resistance to these antimicrobials is of paramount concern.

´ëÇÑÀÓ»ó¹Ì»ý¹°ÇÐȸÁö 2014³â 17±Ç 2È£ p.50 ~ p.57

±Ç¿À±Ù(Kwon O-Geun) - °æ»óºÏµµº¸°Çȯ°æ¿¬±¸¿ø ¹Ì»ý¹°°ú
±èÁø¼®(Kim Jin-Seok) - Áúº´°ü¸®º»ºÎ ±¹¸³º¸°Ç¿¬±¸¿ø ¼öÀμºÁúȯ°ú
±è±Ô¿Á(Kim Gou-Ok) - °æ»óºÏµµº¸°Çȯ°æ¿¬±¸¿ø ¹Ì»ý¹°°ú
ÀÌâÀÏ(Lee Chang-Il) - °æ»óºÏµµº¸°Çȯ°æ¿¬±¸¿ø ¹Ì»ý¹°°ú
Á¤±¤Çö(Jeong Kwang-Hyeon) - °æ»óºÏµµº¸°Çȯ°æ¿¬±¸¿ø ¹Ì»ý¹°°ú
±èÁØ¿µ(Kin Jun-Young) - Áúº´°ü¸®º»ºÎ ±¹¸³º¸°Ç¿¬±¸¿ø ¼öÀμºÁúȯ°ú

Abstract

¹è°æ: ÃÖ±Ù ±¹³»¿Ü¼­´Â 3¼¼´ë ¼¼ÆÈ·Î½ºÆ÷¸°°è¿Í Äû³î·Ð°è Ç×±ÕÁ¦ ³»¼ºÀ» °®´Â »ì¸ð³Ú¶ó¼Ó±Õ¿¡ ´ëÇÑ º¸°í°¡ Áõ°¡ÇϰíÀÖ´Ù. ÀÌ¿Í °ü·ÃÇÏ¿© º» ¿¬±¸¿¡¼­´Â °æºÏÁö¿ª ¼³»çȯÀÚ¿¡¼­ ºÐ¸®µÈ »ì¸ð³Ú¶ó¼Ó±ÕÀ» ´ë»óÀ¸·Î ÇÏ¿© Ç×±ÕÁ¦ ³»¼º °æÇâÀ»È®ÀÎÇϰí ÁÖ¿ä Ç×±ÕÁ¦¿¡ ´ëÇÑ ³»¼ºÁÖ¸¦ ¼±º°ÇÏ¿© ¿øÀÎÀ» ÇϰíÀÚ ÇßÀ¸¸ç Ãß°¡·Î ÀÌ Áö¿ª¿¡¼­ ºÐ¸®µÈ »ì¸ð³Ú¶ó¼Ó±ÕÀÇ À¯ÀüÇÐÀû ¿¬°ü¼ºÀ» È®ÀÎÇϰíÀÚ Çß´Ù.

¹æ¹ý: 2012³âºÎÅÍ 2013³â±îÁö °æºÏÁö¿ª ¼³»çȯÀÚ¿¡¼­ ºÐ¸®µÈ »ì¸ð³Ú¶ó¼Ó±ÕÀ» ´ë»óÀ¸·Î Ç÷ûÇü È®ÀÎÀ» È®ÀÎÇϰí Sensititre ÆÐ³ÎÀ» ÀÌ¿ëÇÏ¿© ÃÖ¼Ò¾ïÁ¦³óµµ(MIC) °ªÀ» ÃøÁ¤ÇÑ ÈÄ WHONet ÇÁ·Î±×·¥À» ÀÌ¿ëÇÏ¿© Ç×±ÕÁ¦ ³»¼º °æÇâÀ» ºÐ¼®ÇÏ¿´´Ù. ÀÌ °á°ú¸¦ Åä´ë·Î È®ÀÎµÈ ÁÖ¿ä Ç×±ÕÁ¦¿¡ ´ëÇØ ³»¼ºÀ» º¸ÀÌ´Â ±ÕÁÖ´Â ¼±º°ÇÏ¿© ±× ³»¼º¿øÀαâÀüÀ» È®ÀÎÇÏ¿´´Ù. Ãß°¡·Î °æºÏÁö¿ª¿¡¼­ ºÐ¸®µÈ ¸ðµç »ì¸ð³Ú¶ó¼Ó±ÕÀº pulsed-field gel electrophoresis (PFGE)¸¦ ÀÌ¿ëÇÏ¿© ±ÕÁÖ°£ À¯ÀüÇÐÀû ¿¬°ü¼ºÀ» È®ÀÎÇÏ¿´´Ù.

°á°ú: °æºÏÁö¿ª¿¡¼­ ¼³»çȯÀÚ¿¡¼­ ºÐ¸®µÈ »ì¸ð³Ú¶ó¼Ó±Õ 30ÁÖ´Â 10°³ÀÇ Ç÷ûÇüÀ¸·Î È®ÀεǾú´Ù. ÀÌ Áß 21ÁÖ°¡ 1°³ÀÌ»óÇ×±ÕÁ¦¿¡ ³»¼ºÀ» º¸¿´°í 4ÁÖ°¡ extended spectrum beta lactamase (ESBL)À» »ý»êÇÏ¿´À¸¸ç 17ÁÖ°¡ Äû³î·Ð°è Ç×±ÕÁ¦ ³»¼ºÁÖ·Î È®ÀÎ µÇ¾ú´Ù. ESBL »ý»ê »ì¸ð³Ú¶ó¼Ó±ÕÀº S. Enteritidis 3ÁÖ¿¡¼­ CTX-M-15Çü ESBLÀ» »ý»êÇÏ¿´°í S. Infantis 1ÁÖ°¡ CTX-M-27Çü ESBLÀ» »ý»êÇÏ´Â °ÍÀ¸·Î È®ÀεǾúÀ¸¸ç IncFII (blaCTX-M-15, blaCTX-M-27)°ú IncHI2 (blaCTX-M-15) replicon À¯ÇüÀÇ plasmid¿¡ bla À¯ÀüÀÚ¸¦ º¸À¯Çϰí ÀÖ¾ú´Ù. 17°³ÀÇ Äû³î·Ð°è Ç×±ÕÁ¦¿¡ ³»¼ºÀÎ ±ÕÁÖ´Â S. Paratyphi 1ÁÖ°¡ gyrA À¯ÀüÀÚÀÇ83¹ø ¾Æ¹Ì³ë»ê Àܱ⿡ º¯À̰¡ ÀÖ´Â °ÍÀ» Á¦¿ÜÇÏ°í ¸ðµÎ 87¹ø ¾Æ¹Ì³ë»ê Àܱ⿡ º¯À̰¡ È®ÀεǾú´Ù. °æºÏÁö¿ª¿¡¼­ ºÐ¸®µÈ»ì¸ð³Ú¶ó¼Ó±ÕÀ» ´ë»óÀ¸·Î Ç÷ûÇüº°·Î PFGE ºÐ¼®ÇÑ °á°ú, S. Enteritidis 13ÁÖ´Â ¿¬°ü°ü°è°¡ 91.26-96.97%·Î À¯ÀüÇÐÀû ±Ù¿øÀÌ À¯»çÇѰÍÀ¸·Î È®ÀεǾúÀ¸³ª S. TyphimuriumÀº 59.63-97.30%·Î ºñ±³Àû ³·Àº ¿¬°ü¼ºÀ» °®´Â °ÍÀ¸·Î È®ÀεǾú´Ù.

°á·Ð: ¼³»çȯÀÚ¿¡¼­ ºÐ¸®µÈ ÁÖ¿ä Ç×±ÕÁ¦¿¡ ´ëÇØ ³»¼ºÀ» º¸ÀÌ´Â »ì¸ð³Ú¶ó¼Ó±ÕµéÀº °æºÏÁö¿ª¿Ü¿¡µµ ±¹³» °øÁߺ¸°Ç¿¡ ½É°¢ÇÑ À§ÇùÀÌ µÉ ¼ö ÀÖÀ» °ÍÀ¸·Î ÃßÁ¤µÇ¸ç ÇâÈÄ ÀÌ¿¡ ´ëÇÑ ÁýÁßÀûÀÎ °¨½Ã ¹× °ü¸®°¡ ÇÊ¿äÇÒ °ÍÀ¸·Î ÆÇ´ÜµÈ´Ù.
Background: Extended-spectrum cephalosporins and fluoroquinolones are important antimicrobials for treating invasive salmonellosis, and emerging resistance to these antimicrobials is of paramount concern.

Methods: A total of 30 Salmonella spp. clinical isolates recovered in Gyeongsangbuk-do from 2012 to2013 were characterized using antibiotic resistance profiles and pulsed-field gel electrophoresis (PFGE).

Results: A high prevalence of multidrug-resistant isolates,mainly showing an ampicillin, nalidixic acid,chloramphenicol resistance pattern, was observed. Four extended-spectrum ¥â-lactamase (ESBL)-producing isolates (3 CTX-M-15 isolates and 1 CTX-M-27 isolate)were found. The blaCTX-M-27 gene was carried byan IncF conjugative plasmid in the S. Infantis isolate.The blaCTX-M-15 gene were carried by an IncF (2 isolates) or IncHI2 (1 isolate) conjugative plasmid in S.Enteritidis. In addition, a single mutation of GyrA, Ser83Thr (1 isolates), Asp87Tyr (9 isolates), Asp87Gly (4 isolates), and Asp87Leu (3 isolates), was detected in nalidixic acid-resistant Salmonella spp. isolates. XbaI PFGE analysis of all isolates revealed more than 19 different pulsotypes. The most common S.Enteritidis PFGE pattern (SEGX01.003) was associated with a larger number of cases of invasive salmonellosis than all other patterns.

Conclusion: The information from our study can assist in source attribution, outbreak investigations, and tailoring of interventions to maximize disease prevention.

Ű¿öµå

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå